503 related articles for article (PubMed ID: 9747583)
1. Light dosimetry for intraperitoneal photodynamic therapy in a murine xenograft model of human epithelial ovarian carcinoma.
Lilge L; Molpus K; Hasan T; Wilson BC
Photochem Photobiol; 1998 Sep; 68(3):281-8. PubMed ID: 9747583
[TBL] [Abstract][Full Text] [Related]
2. Intraperitoneal photodynamic therapy of human epithelial ovarian carcinomatosis in a xenograft murine model.
Molpus KL; Kato D; Hamblin MR; Lilge L; Bamberg M; Hasan T
Cancer Res; 1996 Mar; 56(5):1075-82. PubMed ID: 8640764
[TBL] [Abstract][Full Text] [Related]
3. Phthalocyanine 4 (Pc 4) photodynamic therapy of human OVCAR-3 tumor xenografts.
Colussi VC; Feyes DK; Mulvihill JW; Li YS; Kenney ME; Elmets CA; Oleinick NL; Mukhtar H
Photochem Photobiol; 1999 Feb; 69(2):236-41. PubMed ID: 10048316
[TBL] [Abstract][Full Text] [Related]
4. The effect of fluence rate on tumor and normal tissue responses to photodynamic therapy.
Sitnik TM; Henderson BW
Photochem Photobiol; 1998 Apr; 67(4):462-6. PubMed ID: 9559590
[TBL] [Abstract][Full Text] [Related]
5. In vivo fluence rate and fractionation effects on tumor response and photobleaching: photodynamic therapy with two photosensitizers in an orthotopic rat tumor model.
Iinuma S; Schomacker KT; Wagnieres G; Rajadhyaksha M; Bamberg M; Momma T; Hasan T
Cancer Res; 1999 Dec; 59(24):6164-70. PubMed ID: 10626808
[TBL] [Abstract][Full Text] [Related]
6. Foscan-based photodynamic treatment in vivo: correlation between efficacy and Foscan accumulation in tumor, plasma and leukocytes.
Maugain E; Sasnouski S; Zorin V; Merlin JL; Guillemin F; Bezdetnaya L
Oncol Rep; 2004 Sep; 12(3):639-45. PubMed ID: 15289849
[TBL] [Abstract][Full Text] [Related]
7. In situ light dosimetry during photodynamic therapy of Barrett's esophagus with 5-aminolevulinic acid.
van Veen RL; Aalders MC; Pasma KL; Siersema PD; Haringsma J; van de Vrie W; Gabeler EE; Robinson DJ; Sterenborg HJ
Lasers Surg Med; 2002; 31(5):299-304. PubMed ID: 12430146
[TBL] [Abstract][Full Text] [Related]
8. Performance of a dedicated light delivery and dosimetry device for photodynamic therapy of nasopharyngeal carcinoma: phantom and volunteer experiments.
Nyst HJ; van Veen RL; Tan IB; Peters R; Spaniol S; Robinson DJ; Stewart FA; Levendag PC; Sterenborg HJ
Lasers Surg Med; 2007 Sep; 39(8):647-53. PubMed ID: 17886277
[TBL] [Abstract][Full Text] [Related]
9. Fluence rate as a modulator of PDT mechanisms.
Henderson BW; Busch TM; Snyder JW
Lasers Surg Med; 2006 Jun; 38(5):489-93. PubMed ID: 16615136
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Hypocrellin B in a human bladder tumor model in experimental photodynamic therapy: biodistribution, light dose and drug-light interval effects.
Chin W; Lau W; Cheng C; Olivo M
Int J Oncol; 2004 Sep; 25(3):623-9. PubMed ID: 15289863
[TBL] [Abstract][Full Text] [Related]
11. Photodynamic effectiveness and vasoconstriction in hairless mouse skin after topical 5-aminolevulinic acid and single- or two-fold illumination.
van der Veen N; Hebeda KM; de Bruijn HS; Star WM
Photochem Photobiol; 1999 Dec; 70(6):921-9. PubMed ID: 10628304
[TBL] [Abstract][Full Text] [Related]
12. Photodynamic therapy of actinic keratosis at varying fluence rates: assessment of photobleaching, pain and primary clinical outcome.
Ericson MB; Sandberg C; Stenquist B; Gudmundson F; Karlsson M; Ros AM; Rosén A; Larkö O; Wennberg AM; Rosdahl I
Br J Dermatol; 2004 Dec; 151(6):1204-12. PubMed ID: 15606516
[TBL] [Abstract][Full Text] [Related]
13. Experimental photodynamic therapy for malignant pleural mesothelioma with pegylated mTHPC.
Krueger T; Altermatt HJ; Mettler D; Scholl B; Magnusson L; Ris HB
Lasers Surg Med; 2003; 32(1):61-8. PubMed ID: 12516073
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of chlorin p6 for photodynamic treatment of squamous cell carcinoma in the hamster cheek pouch model.
Dube A; Sharma S; Gupta PK
Oral Oncol; 2006 Jan; 42(1):77-82. PubMed ID: 16140565
[TBL] [Abstract][Full Text] [Related]
15. Photodynamic therapy of human squamous cell carcinoma in vitro and in xenografts in nude mice.
Megerian CA; Zaidi SI; Sprecher RC; Setrakian S; Stepnick DW; Oleinick NL; Mukhtar H
Laryngoscope; 1993 Sep; 103(9):967-75. PubMed ID: 8361317
[TBL] [Abstract][Full Text] [Related]
16. Photofrin-mediated photodynamic therapy induces vascular occlusion and apoptosis in a human sarcoma xenograft model.
Engbrecht BW; Menon C; Kachur AV; Hahn SM; Fraker DL
Cancer Res; 1999 Sep; 59(17):4334-42. PubMed ID: 10485481
[TBL] [Abstract][Full Text] [Related]
17. Potentiation of photodynamic therapy antitumor activity in mice by nitric oxide synthase inhibition is fluence rate dependent.
Henderson BW; Sitnik-Busch TM; Vaughan LA
Photochem Photobiol; 1999 Jul; 70(1):64-71. PubMed ID: 10420844
[TBL] [Abstract][Full Text] [Related]
18. Response surface methodology: an extensive potential to optimize in vivo photodynamic therapy conditions.
Tirand L; Bastogne T; Bechet D; Linder M; Thomas N; Frochot C; Guillemin F; Barberi-Heyob M
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):244-52. PubMed ID: 19604651
[TBL] [Abstract][Full Text] [Related]
19. Induction of intensive tumor suppression by antiangiogenic photodynamic therapy using polycation-modified liposomal photosensitizer.
Takeuchi Y; Kurohane K; Ichikawa K; Yonezawa S; Nango M; Oku N
Cancer; 2003 Apr; 97(8):2027-34. PubMed ID: 12673734
[TBL] [Abstract][Full Text] [Related]
20. Long-term regression of the murine mammary adenocarcinoma, LM3, by repeated photodynamic treatments using meso-tetra (4-N-methylpyridinium) porphine.
Colombo LL; Vanzulli SI; Villanueva A; Cañete M; Juarranz A; Stockert JC
Int J Oncol; 2005 Oct; 27(4):1053-9. PubMed ID: 16142323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
